Latest News and Press Releases
Want to stay updated on the latest news?
-
MENLO PARK, Calif. and SAN DIEGO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Teneobio, Inc., a next generation multi-specific antibody therapeutics company, and Poseida Therapeutics, Inc., a San Diego-based...
-
SAN DIEGO, July 20, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based clinical-stage company translating best-in-class gene engineering technologies into lifesaving...
-
SAN DIEGO, July 19, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, today...
-
SAN DIEGO, April 26, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, provided an...
-
Low dose cohort completed with rapid and clear signs of efficacy in all three patients, and no cytokine release syndrome Data presented at the American Association for Cancer Research (AACR) Annual...
-
SAN DIEGO, April 03, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies,...
-
SAN DIEGO, March 26, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies,...
-
SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies,...
-
SAN DIEGO, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies,...
-
SAN DIEGO, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies,...